Its a big pharma showdown as health care analyst David Williamson discusses whether Merck (NYSE: MRK) or Pfizer (NYSE: PFE) is the better buy. Both stocks have a lot going for them, Merck an exciting pipeline featuring a likely first to market immuno-oncology drug, a hepatitus-c cure, and even a potential treatment for Alzheimer's. Pfizer has a sizable cash horde and an aggressive management team. While losing out on the lower taxes an AstraZeneca deal would have brought, shareholders can look forward to buybacks dividends and a possible huge expansion of its pneumonia vaccine.
Watch and find out in this episode of Market Check-Up, the Motley Fool's health care focused investing show which of these two stocks is the winner.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.